TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral CO‑1686 Monotherapy Versus Single Agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non‑Small Cell Lung Cancer (NSCLC) after Failure of At Least One Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum Doublet Chemotherapy - Regional Cancer Care Associates LLC

Clinical Trials

TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral CO‑1686 Monotherapy Versus Single Agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non‑Small Cell Lung Cancer (NSCLC) after Failure of At Least One Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum Doublet Chemotherapy

Type of Cancer
Lung
Locations
East Brunswick
Sponsor
Clovis Oncology
Protocol Number
CO-1686-020
Cancer Diagnosis
To Learn More Call
201-510-0910